-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: infectious disease
#BIF2012 Company Snapshot: Chimerix
Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >
#BIF2012 Company Snapshot: ContraFect Corporation
The BIO Investor Forum is fast approaching! Below you’ll find our first Company Snapshot of one of the event’s presenting companies, ContraFect Corporation. Continue reading to learn more about ContraFect’s product, their strategies, and what you can expect from their company in the coming months. Company Snapshot What is your company’s lead product or technology? ContraFect is a private company developing biotherapeutics for resistant, life threatening infections. Our lead compound, CF-301, is a bacteriophage lysin, Read More >
BIO Investor Forum Company Snapshot: Immune Design
In the third installment of the Investor Forum Company Snapshots, hear from Immune Design Corp. The CEO of the company, Dr. Carlos Paya, will be presenting next week at the 10th Annual BIO Investor Forum on Tuesday afternoon. Company Snapshot What are the short-term and long-term priorities for your company? Short term: focus on validating in patients a product from each of our two novel technologies. We will be conducting testing of : 1) An Read More >
BIO Investor Forum Company Snapshot: GlobeImmune, Inc.
The BIO Investor Forum will be here before we know it, and we wanted to take the opportunity to highlight some of the companies who will be presenting at the 10th anniversary event. In our first Company Snapshot, hear from Timothy C. Rodell, the President and Chief Executive Officer of GlobeImmune, Inc. Company Snapshot Q: What are the short-term and long-term priorities for your company? Short term – in oncology, completing the GI-4000 phase Read More >
“Contagion” Portrays Our Vulnerability to a Global Pandemic
Earlier this month, the movie Contagion opened in theaters. With a star-studded cast including Matt Damon, Kate Winslet, and Gwyneth Paltrow, this action-thriller about the spread of a deadly virus is sure to attract a large audience. While Hollywood has been known to alter or exaggerate the facts to enhance the storyline, it is reported that Steven Soderbergh and his team aimed to realistically portray a pandemic. As Matt Damon stated in an IMDb interview, Read More >
